The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Mechanism-Based Concepts of Size and Maturity in Pharmacokinetics
Anderson, B. J., & Holford, N. H. G. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094708 · Cited by 1,125
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054
Cyclophosphamide and cancer: golden anniversary
Emadi, A., Jones, R. J., & Brodsky, R. A. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.146 · Cited by 1,050
Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., Staehler, M., Brugger, W., Dietrich, P.-Y., Mendrzyk, R., et al. (2012) · Nature Medicine · doi:10.1038/nm.2883 · Cited by 788
Szakács, G., Váradi, A., Özvegy-Laczka, C., & Sarkadi, B. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.12.010 · Cited by 569
Clinical Pharmacokinetics of Cyclophosphamide
de Jonge, M. E., Huitema, A. D. R., Rodenhuis, S., & Beijnen, J. H. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544110-00003 · Cited by 447
Kanakry, C. G., Ganguly, S., Zahurak, M., Bolaños-Meade, J., Thoburn, C., Perkins, B., Fuchs, E. J., Jones, R. J., Hess, A. D., & Luznik, L. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006960 · Cited by 357
Luznik, L., O'Donnell, P. V., & Fuchs, E. J. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.09.005 · Cited by 336
Rollinghoff, M., Starzinski-Powitz, A., Pfizenmaier, K., & Wagner, H. (1977) · The Journal of Experimental Medicine · doi:10.1084/jem.145.2.455 · Cited by 335
Assessment of aldehyde dehydrogenase in viable cells
Jones, R., Barber, J., Vala, M., Collector, M., Kaufmann, S., Ludeman, S., Colvin, O., & Hilton, J. (1995) · Blood · doi:10.1182/blood.v85.10.2742.bloodjournal85102742 · Cited by 333
Trial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 326
Ninomiya, S., Narala, N., Huye, L., Yagyu, S., Savoldo, B., Dotti, G., Heslop, H. E., Brenner, M. K., Rooney, C. M., & Ramos, C. A. (2015) · Blood · doi:10.1182/blood-2015-01-621474 · Cited by 315
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
Sistigu, A., Viaud, S., Chaput, N., Bracci, L., Proietti, E., & Zitvogel, L. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0245-0 · Cited by 305
Microbiome, Inflammation, and Cancer
Francescone, R., Hou, V., & Grivennikov, S. I. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000048 · Cited by 266
Regulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective
Le, D. T., & Jaffee, E. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3912 · Cited by 240
Ge, Y., Domschke, C., Stoiber, N., Schott, S., Heil, J., Rom, J., Blumenstein, M., Thum, J., Sohn, C., Schneeweiss, A., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1106-3 · Cited by 228
Zhao, J., Cao, Y., Lei, Z., Yang, Z., Zhang, B., & Huang, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0283 · Cited by 211
POLAK, L., & TURK, J. L. (1974) · Nature · doi:10.1038/249654a0 · Cited by 208
Svensson, & Ashton (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00044.x · Cited by 205
Metabolism and Transport of Oxazaphosphorines and the Clinical Implications
Zhang, J., Tian, Q., Yung Chan, S., Chuen Li, S., Zhou, S., Duan, W., & Zhu, Y.-Z. (2005) · Drug Metabolism Reviews · doi:10.1080/03602530500364023 · Cited by 189
Low dose cyclophosphamide: Mechanisms of T cell modulation
Madondo, M. T., Quinn, M., & Plebanski, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.005 · Cited by 188
Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
Viaud, S., Flament, C., Zoubir, M., Pautier, P., LeCesne, A., Ribrag, V., Soria, J.-C., Marty, V., Vielh, P., Robert, C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1259 · Cited by 170
Angulo, I., de las Heras, F. G., Garcı́a-Bustos, J. F., Gargallo, D., Muñoz-Fernández, M. A., & Fresno, M. (2000) · Blood · doi:10.1182/blood.v95.1.212 · Cited by 161
The Immune System in Cancer Prevention, Development and Therapy
Candéias, S. M., & Gaipl, U. S. (2015) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520615666150824153523 · Cited by 153
Penel, N., Adenis, A., & Bocci, G. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.009 · Cited by 149
der Most, R. G. V., Currie, A. J., Mahendran, S., Prosser, A., Darabi, A., Robinson, B. W. S., Nowak, A. K., & Lake, R. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0628-9 · Cited by 147
Ellebæk, E., Engell-Noerregaard, L., Iversen, T. Z., Frøsig, T. M., Ahmad, S. M., Hadrup, S. R., Andersen, M. H., & Svane, I. M. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1242-4 · Cited by 121
Salem, M. L., Kadima, A. N., El-Naggar, S. A., Rubinstein, M. P., Chen, Y., Gillanders, W. E., & Cole, D. J. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211311.28739.e3 · Cited by 119
Tongu, M., Harashima, N., Monma, H., Inao, T., Yamada, T., Kawauchi, H., & Harada, M. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1343-0 · Cited by 118
Dimeloe, S., Frick, C., Fischer, M., Gubser, P. M., Razik, L., Bantug, G. R., Ravon, M., Langenkamp, A., & Hess, C. (2014) · European Journal of Immunology · doi:10.1002/eji.201444879 · Cited by 89
Ninomiya, S., Hara, T., Tsurumi, H., Hoshi, M., Kanemura, N., Goto, N., Kasahara, S., Shimizu, M., Ito, H., Saito, K., et al. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1093-z · Cited by 87
DRUG FOCUS: Pharmacogenetic Studies Related to Cyclophosphamide-Based Therapy
Pinto, N. R., Ludeman, S. M., & Dolan, M. E. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.134 · Cited by 87
Hassan, Svensson, Ljungman, et al. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00090.x · Cited by 77
Peng, S., Lyford-Pike, S., Akpeng, B., Wu, A. A., Hung, C., Hannaman, D., Saunders, J. R., Wu, T. ‐., & Pai, S. I. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1322-5 · Cited by 77
Wirkung eines zyklischen N-Lost-Phosphamidesters auf experimentell erzeugte Tumoren der Ratte1
Brock, N., & Wilmanns, H. (1958) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0028-1114243 · Cited by 76
Inducible costimulator-dependent IL-10 production by regulatory T cells specific for self-antigen
Kohyama, M., Sugahara, D., Sugiyama, S., Yagita∥, H., Okumura, K., & Hozumi, N. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400214101 · Cited by 75
Yoshikawa, T., Hara, T., Tsurumi, H., Goto, N., Hoshi, M., Kitagawa, J., Kanemura, N., Kasahara, S., Ito, H., Takemura, M., et al. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01393.x · Cited by 72
Noguchi, M., Moriya, F., Koga, N., Matsueda, S., Sasada, T., Yamada, A., Kakuma, T., & Itoh, K. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1781-6 · Cited by 72
der Most, R. G. V., Currie, A. J., Robinson, B. W. S., & Lake, R. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402255 · Cited by 70
Kawano, M., Tanaka, K., Itonaga, I., Iwasaki, T., Miyazaki, M., Ikeda, S., & Tsumura, H. (2016) · Oncology Letters · doi:10.3892/ol.2016.4175 · Cited by 69
Salem, M. L., Al-Khami, A. A., El-Naggar, S. A., Diaz-Montero, C. M., Chen, Y., & Cole, D. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902309 · Cited by 63
Trial Watch—Immunostimulation with cytokines in cancer therapy
Vacchelli, E., Aranda, F., Bloy, N., Buqué, A., Cremer, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1115942 · Cited by 60
Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma
Tongu, M., Harashima, N., Yamada, T., Harada, T., & Harada, M. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0797-1 · Cited by 56
Harnessing the Intestinal Microbiome for Optimal Therapeutic Immunomodulation
Viaud, S., Daillère, R., Boneca, I. G., Lepage, P., Pittet, M. J., Ghiringhelli, F., Trinchieri, G., Goldszmid, R. S., & Zitvogel, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0987 · Cited by 48
Engels, C. C., Charehbili, A., van de Velde, C. J. �., Bastiaannet, E., Sajet, A., Putter, H., van Vliet, E. A., van Vlierberghe, R. L. P., Smit, V. T. H. B. M., Bartlett, J. M. S., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3269-7 · Cited by 44
Hsu, F., Chen, T., Chuang, H., Chang, Y.-F., & Hwang, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6628 · Cited by 32
Audemard‐Verger, A., Silva, N. M., Verstuyft, C., Costedoat-Chalumeau, N., Hummel, A., Guern, V. L., Sacré, K., Meyer, O., Daugas, É., Goujard, C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151696 · Cited by 22
Li, K., Chen, F., & Xie, H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s101884 · Cited by 16
An Immunological View of Chemotherapy
Tsung, K., & Norton, J. A. (2015) · Immunotherapy · doi:10.2217/imt.15.62 · Cited by 11
Cited by
Volkmann, E. R., Andréasson, K., & Smith, V. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01692-0 · Cited by 616
Heinhuis, K. M., Ros, W., Kok, M., Steeghs, N., Beijnen, J. H., & Schellens, J. H. M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy551 · Cited by 557
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Wu, J., & Waxman, D. J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.050 · Cited by 320
Ying, M., Yu, Q., Zheng, B., Wang, H., Wang, J., Chen, S., Nie, S., & Xie, M. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.115957 · Cited by 304
Raje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00283-0 · Cited by 212
Metadata
- Authors
- Ahlmann, M., & Hempel, G.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2016-09-19
- Volume
- 78
- Issue
- 4
- Pages
- 661-671
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2521392361
- Cited by
- 499
- References
- 55
- FWCI
- 10.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.